Mega Genomics Ltd. has published its Annual Report for the year ended 31 December 2024. The report highlights the company’s continued growth amid a resilient healthcare market in China. During the reporting period, Mega Genomics Ltd. recorded an increase in both operating revenue and net profit compared to the previous year. The company attributes its performance to a strategic focus on core value, the implementation of targeted market strategies, and ongoing optimization of its business operations. The report also notes the company’s commitment to high-quality development and operational efficiency. The full report can be accessed through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mega Genomics Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260204-12014668), on February 04, 2026, and is solely responsible for the information contained therein.